drugset
drugset / Trial / NCT00195325

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

NCT00195325 ↗

Phase 1 Terminated 45 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedFactorialOpen-labelEct

Summary

The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Timeline

Start
2005-08
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CEVIPABULIN Small molecule — Intravenous

Indications

neoplasm